Agilent Technologies shares rise on Biocare Medical acquisition completion

Yahoo Finance··Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Agilent Technologies shares rose 4.5% to $137.61 after the company announced the completion of its acquisition of Biocare Medical, a clinical pathology firm focused on cancer diagnostics and research. The deal is expected to be accretive to Agilent's top-line growth rate and margin profile within the first year, and to begin contributing to earnings per share approximately 12 months after closing. The acquisition expands Agilent's pathology business and signals a clear path to increased profitability from the new business.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
Agilent Technologies Inc
A
▲ PositiveCapitalrelevance

Acquisition completion expected to be accretive to top-line growth and margins, and to contribute to EPS within 12 months.

© 2026 MarketIVNews